Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models

被引：0
|
作者：
Mcsheehy, P. [1 ]
Boult, J. [2 ]
Robinson, S. [2 ]
Bachmann, F. [1 ]
El Shemerly, M. [1 ]
Kellenberger, L. [1 ]
Lane, H. [1 ]
机构：
[1] Basilea Pharmaceut Int Ltd, Canc Biol, Basel, Switzerland
[2] Inst Canc Res, Div Radiotherapy & Imaging, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
101
引用
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [1] Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models
    McSheehy, Paul M.
    El Shemerly, Mahmoud
    Bachmann, Felix
    Kellenberger, Laurenz
    Lane, Heidi
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [2] Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3
    Mcsheehy, P. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S473 - S473
  • [3] In vivo chamber angiogenesis assay:: A simple growth factor-induced angiogenesis assay for pre-clinical screening of anti-angiogenic compounds
    Kragh, M
    Hjamaa, PVH
    Bramm, E
    Kristjansen, PEG
    Rygaard, J
    Binderup, L
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S133 - S133
  • [4] The anti-angiogenic activity of rPAI-123 inhibits fibroblast growth factor-2 functions
    Drinane, Mary
    Walsh, Jannine
    Mollmark, Jessica
    Simons, Michael
    Mulligan-Kehoe, Mary Jo
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (44) : 33336 - 33344
  • [5] TARGETING FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)-3 IN BLADDER CANCER: PRE-CLINICAL PROOF OF PRINCIPLE
    Gust, Kilian M.
    McConkey, David J.
    Hegarty, Paul K.
    Bondaruk, Jolanta E.
    Czerniak, Bogdan A.
    Dinney, Colin P. N.
    Black, Peter C.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E544 - E544
  • [6] Epidermal growth factor receptor (EGFR) inhibitors: Current and future issues in pre-clinical and clinical development.
    Blackledge, G
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3824S - 3824S
  • [7] The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models
    Chung, Elain Y. L.
    Priebe, Valdemar
    Gaudio, Eugenio
    Kwee, Ivo
    Tarantelli, Chiara
    Rinaldi, Andrea
    Carrassa, Laura
    Testoni, Monica
    Cascione, Luciano
    Broggini, Massimo
    Toretsky, Jeffrey A.
    Zucca, Emanuele
    Bertoni, Francesco
    CANCER RESEARCH, 2015, 75
  • [8] Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease
    Matsuda, Yusaku
    Nonaka, Yosuke
    Futakawa, Satoshi
    Imai, Hirotaka
    Akita, Kazumasa
    Nishihata, Toshiaki
    Fujiwara, Masatoshi
    Ali, Yusuf
    Bhisitkul, Robert B.
    Nakamura, Yoshikazu
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 17 : 819 - 828
  • [9] Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis
    Yang, Guang-Wei
    Jiang, Jin-Song
    Lu, Wei-Qin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (10): : 24011 - 24031
  • [10] Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models
    Stefka, Andrew T.
    Johnson, David
    Rosebeck, Shaun
    Park, Jae-Hyun
    Nakamura, Yusuke
    Jakubowiak, Andrzej J.
    CANCER MEDICINE, 2020, 9 (01): : 324 - 334
12345